Second generation antihistamines in the treatment of seasonal allergic rhinitis due to Parietaria and cypress pollen.
Second generation antihistamines have been employed in the treatment of seasonal allergic rhinitis for many years. However, their effects on two distinctive Mediterranean allergic conditions, viz. Parietaria pollinosis and cypress pollinosis, have been scarcely investigated, so far. A comparative efficacy and side effect trial of astemizole and terfenadine in the treatment of seasonal allergic rhinitis due to either Parietaria or cypress pollen was carried out in 27 adult patients, according to a double-blind, double-dummy parallel-group design. Airborne pollen monitoring allowed comparison of symptom scores with pollen counts. Seven patients (26%) withdrew, due to poor symptom control. In contrast, in a subset of 15 patients who completed the trial, treatment led to a substantial and statistically significant decline in symptom severity in both the astemizole and the terfenadine study group. However, no statistically significant inter-group differences could be detected.
Macchia
L
L
Department of Allergology and Clinical Immunology, University of Bari, 70124 Bari, Italy. g.macchia@area.ba.cnr.it
Caiaffa
M F
MF
Di Paola
R
R
De Michele
G
G
Bariletto
G
G
Iudice
A
A
Tursi
A
A
D000328:Adult; D000485:Allergens / Q000276:immunology*; D016589:Astemizole / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006634:Histamine H1 Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D011058:Pollen / Q000276:immunology*; D006255:Rhinitis, Allergic, Seasonal / Q000188:drug therapy* / Q000276:immunology; D016593:Terfenadine / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
D000485:Allergens; D006634:Histamine H1 Antagonists; D016593:Terfenadine; D016589:Astemizole